Drug Trial Radar · NCT06356311
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
473
Actual
Start
May 3, 2024
Primary completion
Oct 19, 2026
Study completion May 6, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Conditions
- Gastroesophageal Cancer
Interventions
Sacituzumab tirumotecanBiological
Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
Trifluridine-TipiracilDrug
Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
IrinotecanDrug
Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
PaclitaxelDrug
Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
DocetaxelDrug
Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
Rescue medicationsDrug
Participants are required to receive prophylactic mouthwash (steroid mouthwash \[dexamethasone or equivalent\] is highly recommended) to mitigate the onset and severity of stomatitis or oral mucositis. Additionally, participants may receive mucoadhesive hydrogel and oral nystatin suspension or other topical antifungal agents. Additional recommended rescue medications are histamine-1 (H1) receptor antagonist, H2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent, at the investigator's discretion.
Supportive care measuresDrug
Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to ~ 31 months
Locations
168 sites in 24 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0119)
Gilbert, Arizona
UCLA Hematology/Oncology - Santa Monica ( Site 0140)
Los Angeles, California
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129)
Orlando, Florida
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108)
Marietta, Georgia
University of Chicago Medical Center ( Site 0120)
Chicago, Illinois
University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124)
Lexington, Kentucky
The University of Louisville, James Graham Brown Cancer Center-James Graham Brown Cancer Center ( Site 0113)
Louisville, Kentucky
Norton Audubon Hospital-Norton Cancer Institute - Audubon ( Site 0105)
Louisville, Kentucky
Henry Ford Hospital ( Site 0107)
Detroit, Michigan
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0138)
Fargo, North Dakota
Oregon Health and Science University ( Site 0104)
Portland, Oregon
UPMC Hillman Cancer Center ( Site 0126)
Pittsburgh, Pennsylvania
MUSC Hollings Cancer Center-Hematology Oncology ( Site 0122)
Charleston, South Carolina
Sanford Cancer Center ( Site 0136)
Sioux Falls, South Dakota
The West Clinic, PLLC dba West Cancer Center ( Site 0110)
Germantown, Tennessee
Inova Schar Cancer ( Site 0106)
Fairfax, Virginia
Fred Hutchinson Cancer Center ( Site 0111)
Seattle, Washington
Institut Jules Bordet-GastroIntestinal Medical Oncology ( Site 1003)
Anderlecht, Bruxelles-Capitale, Region de, Belgium
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001)
Brussels, Bruxelles-Capitale, Region de, Belgium
UZ Leuven-Digestive Oncology ( Site 1000)
Leuven, Vlaams-Brabant, Belgium
AZ Delta vzw ( Site 1002)
Roeselare, West-Vlaanderen, Belgium
A. C. Camargo Cancer Center ( Site 0409)
São Paulo, Brazil
IBCC - Núcleo de Pesquisa e Ensino ( Site 0402)
São Paulo, Brazil
Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 0405)
Fortaleza, Ceará, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0406)
Natal, Rio Grande do Norte, Brazil
Hospital de Caridade de Ijuí ( Site 0412)
Ijuí, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0400)
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Hematologia e Oncologia ( Site 0404)
Joinville, Santa Catarina, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0401)
Barretos, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0411)
São José do Rio Preto, São Paulo, Brazil
McGill University Health Centre ( Site 0201)
Montreal, Quebec, Canada
James Lind Centro de Investigacion del Cancer ( Site 0506)
Temuco, Araucania, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0503)
Santiago, Region M. de Santiago, Chile
FALP-UIDO ( Site 0500)
Santiago, Region M. de Santiago, Chile
Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 0502)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0501)
Santiago, Region M. de Santiago, Chile
Anhui Provincial Cancer Hospital-medical oncology ( Site 3016)
Hefei, Anhui, China
Second Affiliated hospital of Anhui Medical University-Oncology ( Site 3038)
Hefei, Anhui, China
Chongqing University Three Gorges Hospital ( Site 3036)
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital ( Site 3007)
Fuzhou, Fujian, China
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.